131 related articles for article (PubMed ID: 29053049)
21. Meta-analysis of incidence of rare events.
Lane PW
Stat Methods Med Res; 2013 Apr; 22(2):117-32. PubMed ID: 22218366
[TBL] [Abstract][Full Text] [Related]
22. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data.
Sweeting MJ; Sutton AJ; Lambert PC
Stat Med; 2004 May; 23(9):1351-75. PubMed ID: 15116347
[TBL] [Abstract][Full Text] [Related]
23. Objective Bayesian meta-analysis for sparse discrete data.
Moreno E; Vázquez-Polo FJ; Negrín MA
Stat Med; 2014 Sep; 33(21):3676-92. PubMed ID: 24710961
[TBL] [Abstract][Full Text] [Related]
24. Elicitation of a beta prior for Bayesian inference in clinical trials.
Wu Y; Shih WJ; Moore DF
Biom J; 2008 Apr; 50(2):212-23. PubMed ID: 18085660
[TBL] [Abstract][Full Text] [Related]
25. Updates on cardiovascular outcome trials in diabetes.
Schnell O; Rydén L; Standl E; Ceriello A;
Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Bayesian and frequentist meta-analytical approaches for analyzing time to event data.
Bennett MM; Crowe BJ; Price KL; Stamey JD; Seaman JW
J Biopharm Stat; 2013; 23(1):129-45. PubMed ID: 23331227
[TBL] [Abstract][Full Text] [Related]
27. Bayesian methods for design and analysis of safety trials.
Price KL; Xia HA; Lakshminarayanan M; Madigan D; Manner D; Scott J; Stamey JD; Thompson L
Pharm Stat; 2014; 13(1):13-24. PubMed ID: 23897858
[TBL] [Abstract][Full Text] [Related]
28. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
29. Enhancing pediatric clinical trial feasibility through the use of Bayesian statistics.
Huff RA; Maca JD; Puri M; Seltzer EW
Pediatr Res; 2017 Nov; 82(5):814-821. PubMed ID: 28700566
[TBL] [Abstract][Full Text] [Related]
30. Is there clear and convincing evidence of cardiovascular risk with rosiglitazone?
Kaul S; Diamond GA
Clin Pharmacol Ther; 2011 Jun; 89(6):773-6. PubMed ID: 21593750
[No Abstract] [Full Text] [Related]
31. On the utility of the Dirichlet distribution for meta-analysis of clinical studies.
Sankoh AJ; Al-Osh M; Huque MF
J Biopharm Stat; 1999 May; 9(2):289-306. PubMed ID: 10379695
[TBL] [Abstract][Full Text] [Related]
32. Bayesian estimation in random effects meta-analysis using a non-informative prior.
Bodnar O; Link A; Arendacká B; Possolo A; Elster C
Stat Med; 2017 Jan; 36(2):378-399. PubMed ID: 27790722
[TBL] [Abstract][Full Text] [Related]
33. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
Tanaka A; Node K
Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
[TBL] [Abstract][Full Text] [Related]
34. Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis.
Achana FA; Cooper NJ; Dias S; Lu G; Rice SJ; Kendrick D; Sutton AJ
Stat Med; 2013 Feb; 32(5):752-71. PubMed ID: 22865748
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers in clinical trials: can we move from fortune telling to disease profiling?
de Lemos JA; McGuire DK
Circulation; 2011 Aug; 124(6):663-5. PubMed ID: 21824932
[No Abstract] [Full Text] [Related]
36. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
37. Semiparametric bayesian testing procedure for noninferiority trials with binary endpoints.
Osman M; Ghosh SK
J Biopharm Stat; 2011 Sep; 21(5):920-37. PubMed ID: 21830923
[TBL] [Abstract][Full Text] [Related]
38. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
39. Incretin-based therapy for type 2 diabetes: A real class effect?
Savarese G; Lund LH; Rosano GMC
Int J Cardiol; 2017 Jan; 227():141-142. PubMed ID: 27866064
[No Abstract] [Full Text] [Related]
40. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
Jiang Z; Song Y; Shou Q; Xia J; Wang W
Trials; 2014 Dec; 15():500. PubMed ID: 25528466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
